Mansoor Tanwir, MD
Endocrinology, Diabetes & Metabolism · Church Hill, TNNPI 1538322664
Payments from drug & device makers
Across 591 payments — averaging $140.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$38K
- Lexicon Pharmaceuticals, Inc.$30K
- Xeris Pharmaceuticals, Inc.$5K
- Medtronic$2K
- Dexcom, Inc.$928
- Corcept Therapeutics$904
- plus $7K from 30 others
What the payments were for
- Consulting fees$9752%
- Speaking & faculty fees$32,56861%
- Travel & lodging$7,27814%
- Food & beverage$12,63324%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 81 | $37,800 |
| Lexicon Pharmaceuticals, Inc. | 5 | $29,529 |
| Xeris Pharmaceuticals, Inc. | 59 | $5,434 |
| Medtronic(2 entities) | 15 | $1,544 |
| Dexcom, Inc. | 42 | $928 |
| Corcept Therapeutics | 40 | $904 |
| Lilly USA, LLC | 46 | $847 |
| Tandem Diabetes Care, Inc. | 24 | $618 |
| Bayer | 38 | $571 |
| Amgen(2 entities) | 26 | $517 |
| Sanofi-aventis U.S. LLC | 24 | $486 |
| Novo Nordisk | 31 | $483 |
| Insulet Corporation | 16 | $381 |
| Boehringer Ingelheim | 22 | $379 |
| Recordati_rare_diseases_inc. | 13 | $304 |
| IBSA Pharma Inc. | 10 | $222 |
| AbbVie | 14 | $211 |
| Sequel Med Tech, LLC | 11 | $201 |
| Ascensia Diabetes Care US Inc. | 8 | $195 |
| Mannkind Corporation | 9 | $189 |
| Chiesi USA, Inc. | 8 | $177 |
| Radius Health, Inc. | 8 | $175 |
| Cequr Corporation | 3 | $117 |
| Ascendis Pharma Endocrinology Inc | 5 | $116 |
| BETA Bionics, Inc. | 5 | $98 |
| Nevro Corp. | 4 | $94 |
| AstraZeneca(2 entities) | 4 | $90 |
| Novartis | 4 | $74 |
| Antares Pharma, Inc. | 4 | $71 |
| Kyowa Kirin, Inc. | 3 | $69 |
| Astellas Pharma US Inc | 3 | $47 |
| Pfizer | 2 | $35 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
| Lifescan, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$36,641
- RECORLEV$4,370
- Minimed 670G System$1,146
- DEXCOM G6 TRANSMITTER$230
- MINIMED 780G$228
- FreeStyle Libre$129
- Kerendia$119
- Korlym$113
- Omnipod$101
How this compares
$82,982 in reported general payments places this provider in the 75th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 203 | $334,159 |
| Signifor LarPasireotide Pamoate | 11 | $205,636 |
| MounjaroTirzepatide | 131 | $188,272 |
| JardianceEmpagliflozin | 112 | $143,443 |
| Tresiba Flextouch U-200Insulin Degludec | 59 | $58,009 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 44 | $56,839 |
| ForteoTeriparatide | 12 | $51,369 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 34 | $45,059 |
| Tresiba Flextouch U-100Insulin Degludec | 50 | $39,494 |
| Cinacalcet Hcl | 69 | $36,689 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 16 | $34,981 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $34,078 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $29,817 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 20 | $28,544 |
| Teriparatide | 12 | $27,917 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6 | $483 | $369,140219 claims |
| Lilly USA, LLCMounjaro, Forteo, Trulicity, Humalog, Insulin Lispro | $847 | $272,442193 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Glyxambi | $379 | $224,517191 claims |
| Recordati_rare_diseases_inc.Signifor Lar | $304 | $205,63611 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $486 | $56,83944 claims |
| AstraZenecaFarxiga | $90 | $27,78635 claims |
| AbbVieSynthroid | $211 | $6,43580 claims |
| IBSA Pharma Inc.Tirosint-Sol | $222 | $2,02115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Church Hill
- Stephen SharpNashville$25.9M
- Lisa UsdanMemphis$14.3M
- Kathryn DahirNashville$11M
- David HuffmanChattanooga$2.4M
- Pedro VelasquezMemphis$2.4M
- Craig WierumNashville$1.7M
- Alan CohenMemphis$1.5M
- Terri JerkinsNashville$1.2M
- Pascal DauphinHendersonville$925K
- Aidar GosmanovMemphis$833K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.